Suscribirse

Vulval Aphthous Ulcers in Adolescents Following COVID-19 Vaccination—Analysis of an International Case Series - 01/08/23

Doi : 10.1016/j.jpag.2023.03.006 
Annette Rudolph 1, , Dr. Ruth Savage 1, 2, 3
1 WHO Collaborating Centre for International Drug Monitoring, Uppsala Monitoring Centre, Sweden 
2 New Zealand Pharmacovigilance Centre, Division of Health Sciences, University of Otago, New Zealand 
3 Department of General Practice, University of Otago, Christchurch, New Zealand 

Address correspondence to: Annette Rudolph, MSc.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

ABSTRACT

Study Objective

To review and characterize reports of vulval aphthous ulcers (VAUs) following COVID-19 vaccination in VigiBase, the World Health Organization global database of reported potential adverse effects of medicinal products, to demonstrate the importance and power of case reports for rare suspected adverse reactions and to investigate whether they suggest a potential for COVID-19 vaccination to be a trigger

Methods

Cases reporting the Medical Dictionary for Regulatory Activities’ (MedDRA) preferred term “Vulvovaginal ulceration” and related preferred terms in adolescent patients aged 12-17 years in association with any COVID-19 vaccine were extracted from VigiBase. The cases were clinically reviewed, and causality was assessed by applying the Bradford Hill criteria to the obtained case series.

Results

As of June 30th, 2022, there were 444 reports for the selected Medical Dictionary for Regulatory Activities preferred terms following COVID-19 vaccination in VigiBase. Ninety-four de-duplicated reports concerned adolescent female patients. Thirty-seven cases were clinically consistent with the diagnosis of VAU. On causality assessment, the analyzed case series fulfilled 6 of the 9 Austen Bradford Hill criteria supporting a potential causal relationship.

Conclusion

VAUs can be perceived as a traumatic experience, especially in adolescent patients. There is, furthermore, a risk that the ulcers will be misdiagnosed, resulting in avoidable investigation and treatment burdens for patients. We communicate our findings to support the small number of published case reports and raise awareness of VAUs occurring in a temporal association with COVID-19 vaccination. Furthermore, our analysis supports observations about the value of case reports for the recognition and assessment of rare adverse events.

El texto completo de este artículo está disponible en PDF.

Key Words : Vulval aphthous ulcers, Lipschütz ulcers, COVID-19 vaccine, case series, adolescents, patient safety, pharmacovigilance, Bradford Hill criteria


Esquema


© 2023  Publicado por Elsevier Masson SAS.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 36 - N° 4

P. 383-392 - août 2023 Regresar al número
Artículo precedente Artículo precedente
  • Management of Hematometra and Hematocolpos in Obstructive Mullerian Anomalies by Image-Guided Drainage with Interventional Radiology: A Multi-Institutional Case Series
  • Krista J. Childress, Ashley K. Williams, Aravind Somasundaram, Veronica I. Alaniz, Serena H. Chan, Anne E. Gill
| Artículo siguiente Artículo siguiente
  • Reproductive Health Counseling among Youth with Sickle Cell Disease
  • Charis J. Stanek, Jenna Reich, Charleen I. Theroux, Susan E. Creary, Gwendolyn P. Quinn, Leena Nahata

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.